Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019 Year: 2019
Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002
Homeodomain-interracting protein kinase 2 (HIPK2) in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Eur Respir Rev 2008; 17: 72-73 Year: 2008
Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1426-1433 Year: 2015
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006
Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020 Year: 2020
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
Immunity in idiopathic pulmonary arterial hypertension (IPAH), a role for activated DCs? Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
PDGF and Src tyrosine kinases in pulmonary arterial smooth muscle cells: Effects of dasatinib and nilotinib on pulmonary vascular remodeling Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011
The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
SRC family kinase inhibition reduces NOX4 expression in bronchial epithelial cells from Idiopathic Pulmonary Fibrosis patients Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019
A central role for nuclear factor of activated T cells (NFAT) in human pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study Source: Eur Respir J, 53 (5) 1802472; 10.1183/13993003.02472-2018 Year: 2019